Therapeutics formulated to target cancer stem cells: Is it in our future?

P-Glycoprotein Antibody Functionalized Carbon Nanotube Overcomes the Multidrug Resistance of Human Leukemia Cells

(2010) Ruibin Li et al.   ACS Nano

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

(2010) B. Lowenberg et al.   BLOOD

Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia

(2010) Irene M. Ghobrial et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma

(2010) John D. Hainsworth et al.   JOURNAL OF CLINICAL ONCOLOGY

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors

(2010) Andrew L. Muranyi et al.   LEUKEMIA RESEARCH

Mesenchymal Stem Cells Modified with a Single-Chain Antibody against EGFRvIII Successfully Inhibit the Growth of Human Xenograft Malignant Glioma

(2010) Irina V. Balyasnikova et al.   PLoS One

Therapeutic strategies by modulating oxygen stress in cancer and inflammation

(2009) Jun Fang et al.   ADVANCED DRUG DELIVERY REVIEWS

PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice

(2009) C. Peng et al.   BLOOD

Hedgehog Signaling Is Dispensable for Adult Murine Hematopoietic Stem Cell Function and Hematopoiesis

(2009) Inga Hofmann et al.   Cell Stem Cell

PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like Cells

(2009) Anne-Marie Bleau et al.   Cell Stem Cell

Targeted Elimination of Leukemia Stem Cells; a New Therapeutic Approach in Hemato-Oncology

(2009) B. Cate et al.   CURRENT DRUG TARGETS

Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia

(2009) Alberto M Martelli et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia

(2009) X. Zhao et al.   HAEMATOLOGICA

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Bone marrow mesenchymal stem cells from leukemia patients inhibit growth and apoptosis in serum-deprived K562 cells

(2009) Zhaohui Wei et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability

(2009) B ten Cate et al.   LEUKEMIA

Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia

(2009) M Jawad et al.   LEUKEMIA

Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449

(2009) Charles M. Rudin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

(2009) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia

(2008) Guang-Yao Li et al.   BIOMEDICINE & PHARMACOTHERAPY

Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)

(2008) Ruoping Tang et al.   BMC CANCER

Liposomal daunorubicinversusstandard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia

(2008) Roberto Latagliata et al.   BRITISH JOURNAL OF HAEMATOLOGY

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE